Newsletters and more news updates
The latest newsletter (Autumn 2017) can be downloaded here. Just follow the link or right click the link and save as…
The Urology Patient Experience Survey mentioned in the Spring 2016 newsletter can be found via following link: Urology Patient Experience Survey
David Casley, Prospect Publicity 07860 369064;Â EmailÂ email@example.com
Isotope could be game-changer
A new brachytherapy isotope, Cesium-131, could be a game-changer, a US study indicates (Aug ’17). See
Remarkable results claimed for nuclear medicine treatment
Remarkable results are claimed for an experimental treatment in Australia for advanced prostate cancer patients who had exhausted all their options. It is a disruptive technology in the field of nuclear medicine, pioneered in Germany (Aug â€™17).Â See
Early abiraterone ‘improves survival’
A clinical trial funded by Cancer Research UK has revealed that offering abiraterone earlier in treatment can improve survival in men with advanced prostate cancer. The results are game-changing (Aug ’17). See
New hope for advanced patients
Scientists have developed a blood test that could pick out which men with advanced prostate cancer would benefit from a new drug treatment. The test detects cancer DNA, helping doctors check if precision drugs are working. Cancer Research UK said the test could “greatly improve survivalâ€ť, but added that larger studies are needed to confirm if it is reliable. (Jun â€™17). See
New treatment to be tried out
After a pilot study, an associate Australian professor is to lead a trial of 200 patients with nuclear medicine treatment – what he believes could be a game-changer in the treatment of advanced prostate cancer (July ’17). See
Ignorance over newer tests
Half of urologists are unaware of newer, more sensitive biomarker tests for detecting prostate cancer, according to a worldwide survey of 300 mainly European specialists. The new tests reduce the need for biopsies (July ’17). See
Defeating therapy resistance
A new US study sheds light on a signalling circuit in cells that drives therapy resistance in prostate cancer. Targeting the components of this circuit suppresses advanced cancer development. See.
LaserÂ treatmentÂ success
Surgeons described a new treatment for early stage prostate cancer as “truly transformative”. The approach, tested inÂ Europe, uses lasers and a drug made from deep-sea bacteria to eliminate tumours, but without causing severe side effects. See.
Drastically altering the levels of testosterone could cause cancer cells to die even after they become hormone-resistant, according to new research unveiled in December ’16. See.
After a bombardment of evidence from Prostate Cancer UK, NICE announced in November ’16 they will undertake an exceptional review of this cancer’s clinical guidelines. It will mean lifesaving new diagnosis and treatment sooner than expected. See.
PSA test row
PSA tests may be unnecessary,Â the Academy of Medical Royal Colleges reported (Oct ’16). But Prostate Cancer UK says thy are still the best first step until a more robust oneÂ suitable for a screening programme is devised. Several Prospect members wrote to the BBC or their MP about the situation.Â See. And crowdfunding donations were successfully sought for a new non-invasive and affordable diagnostic test for the early detection of this cancer. See.
World first hailed
Scientists in Belfast claimÂ a major breakthrough in prostate cancer treatment. It is hoped the new discovery, hailed a world first, could help stop the spread of the disease and prevent relapses. Researchers have found that combining hormone therapy with a new drug, OCT1002, can improve treatment effectiveness. See.
Drug targets tumours
A radioactive drug, which behaves likeÂ the substance used to kill Russian ex-spy Alexander Litvinenko, could be used to treat prostate cancer patients. ItÂ targets tumours that have spread to the bones and has been approved by NICE. See.
Early detection claimed
Scientists at Israelâ€™s Weizmann Institute might have found a prostate cancer cure, at least if itâ€™s caught early.Â See.
Urine test created
Scientists have created a urine test for prostate cancer after trials on 155 men in Bristol.Â See
New diagnosis tool; Zytiga affordable
A new risk assessment tool for GPs is set to revolutionise prostate cancer diagnosis.Â See. AndÂ NICE has agreed that abiraterone (Zytiga) is affordable after a lower price was agreed with the makers.Â See.
Southmead charity appeal’s events
See Southmead Hospital Charity’s fundraising eventsÂ hereÂ and you can make a payment.
More accurate predictions?
Patients might be offered a more accurate prediction of their prostate cancer risk with aÂ novel method developed by Cambridge University researchers. See
Biopsies may be ‘out’
Urologists are committed to rolling out diagnostic use of the new MRI scans once their benefits areÂ officially confirmed. The scans make it possible to rule out the need for a biopsy in many men who donâ€™t have a clinically significant prostate cancer. See. Latest on this here. And US researchers have identified a marker of aggressive prostate cancer. See
In a world first, Australian researchers have mapped the entire genome of a prostate tumour (April 2017). See
Improved PSA test in view
BirminghamÂ researchersÂ are working on an improved PSA test. See. And in April 2016Â Tackle reached agreement on the best way to use the PSA test. The guidance, developed with and for GPs and practice nurses, is on better use of the test in men without symptoms.Â See
A new treatment which trains the immune system to attack “liquid” blood cancers has shown “extraordinary” results and could be a potential breakthrough in curing the disease. It is hoped to progress to patients with solid tumours, but this will be challenging and some of those treated suffered severe side effects.Â See